Crescendo Biologics

Crescendo Biologics is developing two proprietary platforms for biological therapeutics from the Babraham Institute: ribosome display for the optimization of antibodies and a transgenic mouse which produces heavy chain only antibodies.

Status current

Associated Fund UK Innovation & Science Seed Fund

Sector Medical / Biotechnology


Associated Team Members

Relevant News

Crescendo Biologics Appoints Dr Barbara Fleck as Head of Intellectual Property

Cambridge, UK: 2 February 2016 – Crescendo Biologics Limited (Crescendo), the drug discovery and developer…

read more

Crescendo Biologics Appoints Dr Kevin Johnson as Chairman

Antibody veteran joins new CEO as Crescendo redirects strategy to Oncology focus  Cambridge, UK: 17…

read more

Crescendo Biologics Launches New Strategy In Oncology Drug Discovery & Development

16 October 2015 Crescendo Biologics Limited, the drug discovery and developer of Humabody™ VH therapeutics,…

read more

Crescendo Biologics Appoints Matthew Roe as Chief Business Officer

8 June 2011 Crescendo Biologics Limited (Crescendo) today announces the appointment of Matthew Roe as…

read more

More Companies in Medical / Biotechnology

Your browser is out-of-date!

Update your browser to view this website correctly.Update my browser now